Committed to Innovative Drug R&D
in the Anti-HIV Field
A Highly Distinctive Human-derived Protein Industrial Chain in China
To Be a Respected and Excellent Pharmaceutical Company
ABOUT AIDEA
Jiangsu Aidea Pharmaceutical Group
Jiangsu Aidea Pharmaceutical Group Co., Ltd. was established in 2009 and listed on the STAR Market of the Shanghai Stock Exchange in 2020 (Stock Code: 688488.SH). The Company is a nationally recognized High-Tech Enterprise and a National-level Specialized, Sophisticated, Distinctive, and Innovative "Little Giant" Enterprise.
Integrating innovative drug R&D, production, and sales, the Company focuses on two core business areas: In the anti-HIV segment, it strives to build a comprehensive value chain from treatment to prevention, positioning itself as a leading national brand in China's HIV field; in the human-derived protein biopharmaceutical segment, it has established a highly competitive full-industry-chain presence in China.
Undertaken 3 projects under the "National New Drug Innovation" Major Project of China Participated in 2 projects under the "Emerging and Major Infectious Disease Prevention and Control" National Science and Technology Major ProjectUndertaken 3 Jiangsu Provincial Key Technological Innovation ProjectsUndertaken 2 Jiangsu Provincial Science and Technology Achievement Transformation Projects
